Skip to main content
AAN.com
Video NeuroImages
October 15, 2018
Free Accessvideo

Dermoskeletics to preserve mobility and function in inclusion body myositis

October 16, 2018 issue
91 (16) 760
A 45-year-old man developed gradual onset of finger flexors and quadriceps weakness. Anti-NT5C1A antibody was positive, and muscle biopsy was consistent with inclusion body myositis. Options to preserve his mobility were explored. The Dermoskeleton uses high-end sensors and advanced artificial intelligence to detect the user's mobility intentions and generate synchronized assistance at the motorized knees. The device considerably improved the patient's 6-minute walk test (720–790 m) and stair climbing capacity (69–140 steps per minute) (videos 1 and 2), as a result of both assistance (primary) and bracing (secondary) factors. Advancing biomechanical technology provides novel options to preserve mobility and function for patients with neuromuscular diseases.
Video 1 Patient climbing stairs without the Dermoskeleton.
Video 2 Patient stair climbing capacity improved with the activated Dermoskeleton.

Acknowledgment

The authors specially thank the PERFORM Centre, Concordia University, for providing the ideal spaces for shooting these videos and for providing an ideal research environment.

Information & Authors

Information

Published In

Neurology®
Volume 91Number 16October 16, 2018
Pages: 760
PubMed: 30323070

Publication History

Published online: October 15, 2018
Published in print: October 16, 2018

Permissions

Request permissions for this article.

Disclosure

The authors report no disclosures relevant to the manuscript. Go to Neurology.org/N for full disclosures.

Study Funding

No targeted funding reported.

Authors

Affiliations & Disclosures

Océane Landon-Cardinal, MD
From the Hôpital Pitié-Salpêtrière (O.L.-C., O.B.), AP-HP, Department of Internal Medicine and Clinical Immunology, Inflammation-Immunopathology-Biotherapy Department (I2B), East Paris Neuromuscular Diseases Reference Center, Inserm U974, France; Departments of Kinesiology and Surgery (F.P.), University of Montreal, B-Temia Inc. (S.B.), Québec City, and Division of Rheumatology (M.H.), Department of Medicine, Jewish General Hospital, Lady Davis Institute, Montréal, Québec, Canada.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
François Prince, PhD
From the Hôpital Pitié-Salpêtrière (O.L.-C., O.B.), AP-HP, Department of Internal Medicine and Clinical Immunology, Inflammation-Immunopathology-Biotherapy Department (I2B), East Paris Neuromuscular Diseases Reference Center, Inserm U974, France; Departments of Kinesiology and Surgery (F.P.), University of Montreal, B-Temia Inc. (S.B.), Québec City, and Division of Rheumatology (M.H.), Department of Medicine, Jewish General Hospital, Lady Davis Institute, Montréal, Québec, Canada.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Stéphane Bédard, PEng, MSc
From the Hôpital Pitié-Salpêtrière (O.L.-C., O.B.), AP-HP, Department of Internal Medicine and Clinical Immunology, Inflammation-Immunopathology-Biotherapy Department (I2B), East Paris Neuromuscular Diseases Reference Center, Inserm U974, France; Departments of Kinesiology and Surgery (F.P.), University of Montreal, B-Temia Inc. (S.B.), Québec City, and Division of Rheumatology (M.H.), Department of Medicine, Jewish General Hospital, Lady Davis Institute, Montréal, Québec, Canada.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
Patents: (1) Load Distribution Device for Human Joints ? B01, US 9,370,439, CA 2,803,035, EP 2555720. An IP protection on the dermoskeletal concept for any joint-segment body structure of the human body. This patent represents the core of the technological platform behind the B-Temia?s dermoskeletal technology. ▪ US. provisory deposit ? 7 April 2010. ▪ US Patent ? 21 June 2016. ▪ CA application ? 18 February 2011. ▪ EP Patent - 12 April 2017
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
(1) B-Temia Inc., President and CEO, 2010
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
(1) B-Temia Inc.
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
(1) B-Temia Inc., 8 years
Legal Proceedings:
1.
NONE
Olivier Benveniste, MD, PhD
From the Hôpital Pitié-Salpêtrière (O.L.-C., O.B.), AP-HP, Department of Internal Medicine and Clinical Immunology, Inflammation-Immunopathology-Biotherapy Department (I2B), East Paris Neuromuscular Diseases Reference Center, Inserm U974, France; Departments of Kinesiology and Surgery (F.P.), University of Montreal, B-Temia Inc. (S.B.), Québec City, and Division of Rheumatology (M.H.), Department of Medicine, Jewish General Hospital, Lady Davis Institute, Montréal, Québec, Canada.
Disclosure
Scientific Advisory Boards:
1.
Csl Behring Novartis LFB
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
(1) CSL Behring: funding for travel at the ACR 2014 conference (2) LFB: funding for travel at the ICNMD 2014 conference, ACR 2017
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
(1) Novartis (2) CSL Behring (3) Neovacs
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
(1) LFB,(2) Novartis, (3) Shire, (4) CSL Behring, (5) Neovacs
Research Support, Government Entities:
1.
(1) DGOS/INSERM, (2) PHRC
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
(1) AFM, (2) The Myositis Association
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Marie Hudson, MD, MPH
From the Hôpital Pitié-Salpêtrière (O.L.-C., O.B.), AP-HP, Department of Internal Medicine and Clinical Immunology, Inflammation-Immunopathology-Biotherapy Department (I2B), East Paris Neuromuscular Diseases Reference Center, Inserm U974, France; Departments of Kinesiology and Surgery (F.P.), University of Montreal, B-Temia Inc. (S.B.), Québec City, and Division of Rheumatology (M.H.), Department of Medicine, Jewish General Hospital, Lady Davis Institute, Montréal, Québec, Canada.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE

Notes

Correspondence Dr. Landon-Cardinal [email protected]

Author Contributions

O. Landon-Cardinal, F. Prince, S. Bédard, and M. Hudson: conceptualization and design. O. Landon-Cardinal, F. Prince, and M. Hudson: acquisition of data. O. Landon-Cardinal, F. Prince, O. Benveniste, and M. Hudson: analysis and interpretation of data. O. Landon-Cardinal, F. Prince, S. Bédard, O. Benveniste, and M. Hudson: critical revision of the manuscript for important intellectual content.

Metrics & Citations

Metrics

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Possible future avenues for myositis therapeutics: DM, IMNM and IBM, Best Practice & Research Clinical Rheumatology, 36, 2, (101762), (2022).https://doi.org/10.1016/j.berh.2022.101762
    Crossref
  2. Functioning in adult patients with idiopathic inflammatory myopathy: Exploring the role of environmental factors using focus groups, PLOS ONE, 16, 2, (e0244959), (2021).https://doi.org/10.1371/journal.pone.0244959
    Crossref
  3. Autoimmune myositis—Mechanism and therapy development, Neurology and Clinical Neuroscience, 10, 6, (279-288), (2021).https://doi.org/10.1111/ncn3.12563
    Crossref
Loading...

View Options

View options

Full Text

View Full Text

Get Access

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

Purchase this article to get full access to it.

Purchase Access, $39 for 24hr of access

Media

Figures

Other

Tables

Share

Share

Share article link

Share